Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04587856

Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients

Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
38 (estimated)
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a biological study for adult MDS patients who undergo HSCT procedure. Viable bone marrow samples will be collected and cryopreserved from MDS patients before transplantation and at clinical disease recurrence. CD34+ blast cells at disease relapse after HSCT will be compared with CD34+ cells collected before transplant to study genomic and transcriptomic changes.

Detailed description

This is a biological study for adult MDS patients who undergo HSCT procedure.The research is focused on the study of biological mechanisms of disease relapse after HSCT in MDS to provide the rationale to develop pre-emptive strategies in patients with high risk of transplant failure. Viable bone marrow samples will be collected and cryopreserved from MDS patients before transplantation and at clinical disease recurrence. CD34+ blast cells at disease relapse after HSCT will be compared with CD34+ cells collected before transplant by using Single-cell sequencing. To study genomic and transcriptomic changes in CD34+ blast cells at disease relapse after HSCT will be used TARGET-seq in parallel with unbiased whole-transcriptome analysis.

Conditions

Interventions

TypeNameDescription
OTHERbone marrow withdrawalbone marrow samples evaluation

Timeline

Start date
2021-02-12
Primary completion
2025-03-01
Completion
2025-03-01
First posted
2020-10-14
Last updated
2024-10-22

Locations

7 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT04587856. Inclusion in this directory is not an endorsement.